Franklin Resources, Inc. (NYSE:BEN)
Franklin Resources, Inc. (NYSE:BEN) represented a move of -0.9 percent or $0.23 per share and closed its previous day trading session at $32.94. 2.28 Million Shares were traded in the last trading session with an Average Volume of 3.53 Million Shares. The stock currently has a Market Capitalization of 17.83 Billion.
Franklin Resources, Inc. is a global investment management organization known as Franklin Templeton Investments. They have an extensive global presence, including offices in 33 countries and clients in more than 170. Our common stock is listed on the New York Stock Exchange under the ticker symbol BEN and is included in the Standard & Poor’s 500(r) Index.
The stock traded between $31.67 and $47.65 over 1-Year time period showing its price to sales ratio of 2.76. Franklin Resources, Inc. (NYSE:BEN) is currently showing an DECREASING volatility over a period of 10-Days while the 20-Days Volatility showing a DECREASING trend.
Right now, the stock has a 50-Day Simple Moving Average of $-2.06 and 200-Day Simple Moving Average of $-11.7. Its Price to Free Cash Flow is 20.61 and Price to Book of 1.78.
Analyst’s recommended the stock as 3.3 where 1 represents Strong Buy and 5 represents Sell.
ZIOPHARM Oncology Inc (NASDAQ:ZIOP)
In the last trading session, ZIOPHARM Oncology Inc (NASDAQ:ZIOP) added its value by -8.61% closing at the price of $3.29. The stock currently has market capitalization of 486.03 Million, with average volume of 1.16 Million shares.
Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is showing beta of 1.62. This particular value of beta suggests that ZIOPHARM Oncology Inc (NASDAQ:ZIOP) has historically moved 162% for every 100% move in the benchmark, based on price level.
EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for ZIOPHARM Oncology Inc (NASDAQ:ZIOP) is at $-0.54.
The stock currently has RSI of 27.96. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.
ZIOPHARM Oncology, Inc. is a biopharmaceutical company engaged in the development and commercialization of a diverse, risk-sensitive portfolio of in-licensed cancer drugs to address unmet medical needs. The Company applies new insights from molecular and cancer biology to understand the efficacy and safety limitations of approved and developmental cancer therapies and identifies proprietary and related molecules for better patient treatment.